You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Get the latest updates or take a self-assessment.

Clinical Utility of Multigene Profiling Assays in Invasive Early-Stage Breast Cancer

ID: MOAC 4 Jun 2016
Type of Content: Guidelines & Advice, Clinical
Document Status: In-Review
M.C. Chang, L.H. Souter, S. Kamel-Reid, M. Rutherford, P. Bedard, M. Trudeau, J. Hart, A. Eisen, Molecular Oncology Advisory Committee

Guideline Objective

  1. To determine the level of evidence supporting the clinical validity and utility for the profiling assays in question
  2. To determine whether certain breast cancer patient populations in Ontario would benefit from alternative tests (in addition to Oncotype DX)

Patient Population

Women diagnosed with invasive early-stage breast cancer for whom further information is needed for treatment decision making

Intended Guideline Users

Clinicians, policy makers, and the Ontario Ministry of Health and Long-Term Care

Research Question(s)

  1. Given that there are now multiple multigene assays that can predict for recurrence in patients with invasive breast cancer, what is the level of evidence supporting the clinical validity and utility for each of these assays?
  2. Given that Oncotype DX is part of standard practice in Ontario, what is the evidence that other assays can complement or replace Oncotype DX for certain clinical utilities?
pdf download Summary (PDF) (218.22 KB)